LINC01489: A Potential Drug Target and Biomarker (G101928340)

Target Name: LINC01489

NCBI ID: G101928340

LINC01489

Other Name(s): Long intergenic non-protein coding RNA 1489 | long intergenic non-protein coding RNA 1489

LINC01489: A Potential Drug Target and Biomarker

Non-protein-coding RNAs (NP-CRNAs) have emerged as a promising source of drug targets and biomarkers due to their diverse functions and unique mechanisms of regulation. One such RNA, LINC01489, has shown promise as a potential drug target and biomarker.

LINC01489 is a long intergenic non-protein-coding RNA (lncRNA) with a length of approximately 21.1 kilobases (kb) and a unique 5' end that consists of 12 exons followed by a 3' exon. It is located between the 5' and 3' ends of the intron 1489 in chromosome 6 (6p) and has been identified as a potential drug target in various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

The functional characterization of LINC01489 has led to its identification as a negative regulator of the gene encoding the protein T-cell receptor (TCR), which is a critical regulator of immune responses and a potential drug target in autoimmune diseases. LINC01489 has been shown to physically interact with the T-cell receptor by forming a complex with its C-terminus. This interaction between LINC01489 and TCR has led to the inhibition of TCR-mediated signaling, thereby targeting the protein for potential drug development.

In addition to its potential as a TCR inhibitor, LINC01489 has also been shown to play a role in regulating the expression of genes involved in cell adhesion, migration, and invasion. These functions are of interest in the context of cancer, where the regulation of cell adhesion and migration is often a key mechanism of tumor progression. LINC01489 has been shown to contribute to the regulation of genes involved in cell adhesion and migration by binding to the protein known as E-cadherin, which is involved in cell-cell adhesion.

The potential utility of LINC01489 as a drug target and biomarker is further underscored by its expression in various disease tissues and cell types, including cancer cells, neurodegenerative neurons, and glial cells in neuroimmune disease. Additionally, LINC01489 has been shown to be expressed in various tissues and conditions associated with disease, including cancer, neurodegenerative diseases, and autoimmune disorders. This Expression Analysis has the potential to identify LINC01489 as a potential biomarker for disease diagnosis and monitoring.

In conclusion, LINC01489 is a long intergenic non-protein-coding RNA that has shown promise as a potential drug target and biomarker. Its unique mechanisms of regulation, including its interaction with the T-cell receptor, its regulation of cell adhesion and migration, and its expression in various disease tissues make it an attractive target for drug development. Further research is needed to fully understand the functional role of LINC01489 in disease and to develop effective strategies for its targeted therapy.

Protein Name: Long Intergenic Non-protein Coding RNA 1489

The "LINC01489 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC01489 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets